Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medsol RX vs Wisp

Medsol RX
Graded #306

Lower grade

vs+14
Wisp
Graded #59

Higher grade

The verdict

Wisp takes it — 75/100 to 61/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +38
45
83
Dose & formulationWisp +24
64
88
Clinical oversightWisp +3
79
82
Labs & monitoringEven
53
53
FulfillmentMedsol RX +17
83
66
Contract termsWisp +14
41
55
Medsol RX · left barWisp · right bar

The numbers

MetricMedsol RXWisp
WeighScore61/10075/100
GradeCC
Scorecard rank#306#59
Semaglutide$209/mo (compounded)$225/mo (compounded oral)
Tirzepatide$250/mo (compounded)$99/mo (starting dose, brand-name)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Medsol RX

Graded #306 · C

Strengths

  • Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
  • Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
  • Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
  • Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons

Where it loses points

  • Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
  • No legal entity name published on the site
  • Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
  • Compounded GLP-1s are not FDA-approved (the site discloses this)
Wisp

Graded #59 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard